Jiang Bowen, Xie Deqian, Wang Shijin, Li Xiunan, Wu Guangzhen
Department of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
Front Genet. 2023 Feb 24;14:1091223. doi: 10.3389/fgene.2023.1091223. eCollection 2023.
During the last decade, non-invasive methods such as liquid biopsy have slowly replaced traditional imaging and invasive pathological methods used to diagnose and monitor cancer. Improvements in the available detection methods have enabled the early screening and diagnosis of solid tumors. In addition, advances in early detection methods have made the continuous monitoring of tumor progression using repeat sampling possible. Previously, the focus of liquid biopsy techniques included the following: 1) the isolation of circulating tumor cells, circulating tumor DNA, and extracellular tumor vesicles from solid tumor cells in the patient's blood; in addition to 2) analyzing genomic and proteomic data contained within the isolates. Recently, there has been a rapid devolvement in the techniques used to isolate and analyze molecular markers. This rapid evolvement in detection techniques improves their accuracy, especially when few samples are available. In addition, there is a tremendous expansion in the acquisition of samples and targets for testing; solid tumors can be detected from blood and other body fluids. Test objects have also expanded from samples taken directly from cancer to include indirect objects affected in cancer development. Liquid biopsy technology has limitations. Even so, this detection technique is the key to a new phase of oncogenetics. This review aims to provide an overview of the current advances in liquid biopsy marker selection, isolation, and detection methods for solid tumors. The advantages and disadvantages of liquid biopsy technology will also be explored.
在过去十年中,诸如液体活检等非侵入性方法已逐渐取代用于诊断和监测癌症的传统成像及侵入性病理方法。现有检测方法的改进使得实体瘤的早期筛查和诊断成为可能。此外,早期检测方法的进步使通过重复采样对肿瘤进展进行持续监测成为可能。以前,液体活检技术的重点包括以下方面:1)从患者血液中的实体瘤细胞中分离循环肿瘤细胞、循环肿瘤DNA和细胞外肿瘤囊泡;此外还包括2)分析分离物中包含的基因组和蛋白质组数据。最近,用于分离和分析分子标志物的技术有了快速发展。检测技术的这种快速发展提高了其准确性,尤其是在样本量较少的情况下。此外,样本采集和检测靶点的范围也有了极大扩展;可以从血液和其他体液中检测实体瘤。检测对象也从直接取自癌症的样本扩展到包括受癌症发展影响的间接对象。液体活检技术存在局限性。即便如此,这种检测技术仍是肿瘤遗传学新阶段的关键。本综述旨在概述实体瘤液体活检标志物选择、分离和检测方法的当前进展。同时还将探讨液体活检技术的优缺点。